Detailed material

  • Evidence-Based Complementary and .....
實證醫學(輔助藥物)醫學期刊

期刊主題 Research Artcle

Safety and Efficacy of Tien-Hsien Liquid Practical in Patients with Refractory Metastatic Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IIa Trial.

研究作者 Research author

Wen-Hung Kuo,1 Chien-An Yao,2 Chih Hui Lin,3 and King-Jen Chang1,4

研究單位 Research unit:

1 Department of General Surgery, National Taiwan University Hospital,

  Taipei, Taiwan

2 Department of Family Medicine, National Taiwan University Hospital,

  Taipei, Taiwan

3 Gerent Biotech Co., Ltd., Taichung, Taiwan

4 Department of Surgery, Cheng Ching General Hospital,

  Taichung, Taiwan

 

研究單位 Conclusions:

Our findings suggest that an oral administration of 20 mL THL-P three times a day for 24 weeks significantly improves the QOL, increases the physical, role, emotional, and cognitive functioning, decreases fatigue and systemic therapy side effects, and has immunomodulating effects on lymphocytes in patients with refractory metastatic breast cancer. Additionally, THL-P treatment did not induce any severe adverse events. Together, these findings suggest that THL-P is a safe and effective CAM for patients with refractory metastatic breast cancer.

期刊介紹 Journal Introduction:

The Evidence-Based Complementary and Alternative Medicine was established in 2004 by Professor Edwin L. Cooper. It is a medical journal with an international prospective that mainly collects papers on complementary and alternative medicine and encourages exploring folk medicine and new therapies for further understanding and examination.

Impact Factor for 2012 is 4.774.

 

期刊連結 Link to Journal:

website address:http://www.hindawi.com

重要聲明 Disclaimer

Pictures of this webpage are from the website of the Evidence-Based Complementary and Alternative Medicine (http://www.hindawi.com/). 
All the privilege of intellectual property is owned by the Evidence-Based Complementary and Alternative Medicine.